title: Myrislignan attenuates lipopolysaccharide-induced inflammation reaction in murine macrophage cells through inhibition of NF-κB signalling pathway activation.
abstract: Myrislignan is a new kind of lignan isolated from Myristica fragrans Houtt. Its antiinflammatory effects have not yet been reported. In the present study, the antiinflammatory effects and the underlying mechanisms of myrislignan in lipopolysaccharide (LPS)-induced inflammation in murine RAW 264.7 macrophage cells were investigated. Myrislignan significantly inhibited LPS-induced production of nitric oxide (NO) in a dose-dependent manner. It inhibited mRNA expression and release of interleukin-6 (IL-6) and tumour necrosis factor-α (TNF-α). This compound significantly inhibited mRNA and protein expressions of inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-2) dose-dependently in LPS-stimulated macrophage cells. Further study showed that myrislignan decreased the cytoplasmic loss of inhibitor κB-α (IκB-α) protein and the translocation of NF-κB from cytoplasm to the nucleus. Our results suggest that myrislignan may exert its antiinflammatory effects in LPS-stimulated macrophages cells by inhibiting the NF-κB signalling pathway activation.
authors.affiliation: Southern Medical University, Guangdong International Cooperation Base of Science and Technology, Guangdong Key Laboratory for New Drug-Screening, Guangzhou 510515, China.
authors.forename: Hong
authors.initials: H
authors.lastname: Jin
authors.forename: Zheng-Guang
authors.initials: ZG
authors.lastname: Zhu
authors.forename: Peng-Jiu
authors.initials: PJ
authors.lastname: Yu
authors.forename: Guang-Fa
authors.initials: GF
authors.lastname: Wang
authors.forename: Jun-Yan
authors.initials: JY
authors.lastname: Zhang
authors.forename: Jing-Rong
authors.initials: JR
authors.lastname: Li
authors.forename: Rui-Ting
authors.initials: RT
authors.lastname: Ai
authors.forename: Zhong-Huang
authors.initials: ZH
authors.lastname: Li
authors.forename: Yuan-Xin
authors.initials: YX
authors.lastname: Tian
authors.forename: Wei Xu Jia-Jie
authors.initials: WX
authors.lastname: Zhang
authors.forename: Shu-Guang
authors.initials: SG
authors.lastname: Wu
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D002460:Cell Line; D051546:Cyclooxygenase 2 / Q000378:metabolism; D020672:I-kappa B Proteins / Q000378:metabolism; D007249:Inflammation / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D017705:Lignans / Q000494:pharmacology*; D008070:Lipopolysaccharides; D008264:Macrophages / Q000187:drug effects*; D051379:Mice; D000072000:NF-KappaB Inhibitor alpha; D016328:NF-kappa B / Q000378:metabolism*; D009569:Nitric Oxide / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: C531053:2-(4-allyl-2,6-dimethoxyphenoxy)-1-(4-hydroxy-3-methoxyphenyl)propan-1-ol; D000893:Anti-Inflammatory Agents; D020672:I-kappa B Proteins; D015850:Interleukin-6; D017705:Lignans; D008070:Lipopolysaccharides; D016328:NF-kappa B; C000606205:Nfkbia protein, mouse; D014409:Tumor Necrosis Factor-alpha; D000072000:NF-KappaB Inhibitor alpha; D009569:Nitric Oxide; D052247:Nitric Oxide Synthase Type II; C496317:Nos2 protein, mouse; C077623:Ptgs2 protein, mouse; D051546:Cyclooxygenase 2